Patents by Inventor Richard Franck

Richard Franck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Arm Powered Cycle
    Publication number: 20230286609
    Abstract: An arm powered cycle has an arm drive with a hand bar. Oscillating fore and aft movement of the hand bar is converted to rotational movement to drive a driven wheel by a dual, reverse motion slip clutch. The hand bar can have a U-shaped yoke with a seat positioned between uprights of the yoke. The yoke can be combined with an integrated steering mechanism to both drive the driven wheel and turn a directional wheel. A combiner can combine motion from the arm drive and a leg drive.
    Type: Application
    Filed: March 8, 2022
    Publication date: September 14, 2023
    Inventor: Richard Francks
  • Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases
    Patent number: 8252909
    Abstract: The invention is directed to compounds of formula (I) wherein X is O or NH; R? is a hydrocarbon chain; R3 and R4 are hydrogen, OH or a monosaccharide; R5 is hydrogen or a monosaccharide; Q? is optionally present and may be a C1-10 hydrocarbon; X? is optionally present and may be O, S or NR8; and Q3 may be a hydrocarbon or hydrogen. The invention is also directed to the use of the compounds for treating cancer, infectious diseases and autoimmune diseases. The invention is also directed to syntheses of the compounds of formula (I).
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: August 28, 2012
    Assignees: New York University, The Research Foundation of the City University of New York
    Inventors: Moriya Tsuji, Guangwu Chen, Richard Franck, Guangli Yang
  • Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
    Patent number: 7771726
    Abstract: The present invention relates to methods and compositions for augmenting an immunogenicity of an antigen in a mammal, comprising administering said antigen together with an adjuvant composition that includes a synthetic glycolipid compound of Formula I, as described herein. According to the present invention, the use of a compound of Formula I as an adjuvant is attributed at least in part to the enhancement and/or extension of antigen-specific Th1-type responses, in particular, CD8+ T cell responses. The methods and compositions of the present invention can be useful for prophylaxis and treatment of various infectious and neoplastic diseases.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: August 10, 2010
    Assignees: New York University, The Research Foundation of the City University of New York, Aaron Diamond Aids Research Center
    Inventors: Moriya Tsuji, John Schmieg, Richard Franck, Yaoxing Huang
  • Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
    Patent number: 7273852
    Abstract: The invention is directed to compounds of formula (I) wherein X is O or NH; R? is a hydrocarbon chain; R3 and R4 are hydrogen, OH or a monosaccharide; R5 is hydrogen or a monosaccharide; Q? is optionally present and may be a C1-10 hydrocarbon; X? is optionally present and may be O, S or NR8; and Q3 may be a hydrocarbon or hydrogen. The invention is also directed to the use of the compounds for treating cancer, infectious diseases and autoimmune diseases. The invention is also directed to syntheses of the compounds of formula (I).
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: September 25, 2007
    Assignee: The Research Foundation of the City University of New York
    Inventors: Moriya Tsuji, Guangwu Chen, Richard Franck, Guangli Yang
  • Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases
    Publication number: 20060019246
    Abstract: The invention is directed to compounds of formula (I) wherein X is O or NH; R? is a hydrocarbon chain; R3 and R4 are hydrogen, OH or a monosaccharide; R5 is hydrogen or a monosaccharide; Q? is optionally present and may be a C1-10 hydrocarbon; X? is optionally present and may be O, S or NR8; and Q3 may be a hydrocarbon or hydrogen. The invention is also directed to the use of the compounds for treating cancer, infectious diseases and autoimmune diseases. The invention is also directed to syntheses of the compounds of formula (I).
    Type: Application
    Filed: July 29, 2005
    Publication date: January 26, 2006
    Applicants: New York University, Research Foundation of the City University of New York
    Inventors: Moriya Tsuji, Guangwu Chen, Richard Franck, Guangli Yang
  • Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
    Publication number: 20050222048
    Abstract: The invention is directed to novel compounds of formulae (I), (II) and (III): wherein X is O or NH; R3 is OH or a monosaccharide and R4 is hydrogen, or R3 is hydrogen and R4 is OH or a monosaccharide; R5 is hydrogen or a monosaccharide; and pharmaceutically acceptable salts or esters thereof. The invention is also directed to the use of the compounds both directly and as immune adjuvants for treating cancer, infectious diseases and autoimmune diseases. The invention is also directed to syntheses of the intermediates which can be used to make these novel compounds.
    Type: Application
    Filed: March 31, 2005
    Publication date: October 6, 2005
    Applicants: The Research Foundation of The City University of New York, New York University
    Inventors: Moriya Tsuji, Richard Franck, Guangwu Chen
  • Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
    Publication number: 20050192248
    Abstract: The present invention relates to methods and compositions for augmenting an immunogenicity of an antigen in a mammal, comprising administering said antigen together with an adjuvant composition that includes a synthetic glycolipid compound of Formula I, as described herein. According to the present invention, the use of a compound of Formula I as an adjuvant is attributed at least in part to the enhancement and/or extension of antigen-specific Th1-type responses, in particular, CD8+ T cell responses. The methods and compositions of the present invention can be useful for prophylaxis and treatment of various infectious and neoplastic diseases.
    Type: Application
    Filed: October 8, 2004
    Publication date: September 1, 2005
    Applicant: NYU Medical Center
    Inventors: Moriya Tsuji, John Schmieg, Richard Franck, Yaoxing Huang